GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...
In recent years, non-alcoholic fatty liver disease (NAFLD) has developed rapidly worldwide and has become the main cause of chronic liver disease. With the increase in prevalence, the incidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback